Accession Number:

ADA467973

Title:

Role of Growth Hormone in Prostate Cancer

Descriptive Note:

Final rept. 19 Jan 2004-18 Jan 2007

Corporate Author:

ILLINOIS UNIV AT CHICAGO

Personal Author(s):

Report Date:

2007-02-01

Pagination or Media Count:

28.0

Abstract:

We have established a GH-deficient prostate cancer model TagGhdrdr rat indicating that a reduction in GH andor IGF-I can significantly inhibit prostate carcinogenesis in this model in contrast to GH wild-type controls ProbasinTag, TagGh. TagGh TagGhdrdr and age-matched non-Tag controls were sacrificed at 10, 25 and 52 weeks of age. While real-time RT PCR and immunohistochemical analysis revealed the significantly increased levels of prostate GHR and the dramatically reduced levels of prostate IGF-1R P0.0001 in TagGh during prostate cancer progression the loss of prostate GHR and the increase of IGF-1R were observed in TagGhdrdr. However there was no significant change in either serum or prostate IGF-1 level that can be correlated with prostate cancer progression or the resistance of TagGhdrdr to prostate carcinogenesis. These findings are consistent with the hypothesis that GH signaling plays a significant role in prostate carcinogenesis and suggest that GH antagonists may be effective agent against prostate cancer.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE